Personalized, parcel‐guided rTMS for the treatment of major depressive disorder: Safety and proof of concept

BACKGROUND: Not all patients with major depressive disorder (MDD) benefit from the US Food and Drug Administration‐approved use of repetitive transcranial magnetic stimulation (rTMS) at the dorsolateral prefrontal cortex. We may be undertreating depression with this one‐size‐fits‐all rTMS strategy....

Descripción completa

Detalles Bibliográficos
Autores principales: Tang, Si Jie, Holle, Jonas, Dadario, Nicholas B., Lesslar, Olivia, Teo, Charles, Ryan, Mark, Sughrue, Michael, Yeung, Jacky T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10636393/
https://www.ncbi.nlm.nih.gov/pubmed/37798655
http://dx.doi.org/10.1002/brb3.3268

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10636393/
https://www.ncbi.nlm.nih.gov/pubmed/37798655
http://dx.doi.org/10.1002/brb3.3268

Ejemplares similares